Bortezomib

IUPAC Name: [(1R)-3-Methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl] amino]butyl]boronic acid
Molecular Formula: C₁₉H₂₅BN₄O₄
Molecular Weight: 384.24 g/mol
SMILES: O=C(N[C@@H](C(=O)N[C@@H](B(O)O)CC(C)C)Cc1ccccc1)c2nccnc2 Copy 
InChI: InChI=1/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m1/s1
Product Categories: Boron Derivatives; Inhibitors; Intermediates & Fine Chemicals; Pharmaceuticals
Classification Code: Antineoplastic Agents; Enzyme Inhibitors; Protease Inhibitors; Treatment of multiple cancers, including multiple myeloma, chronic lymphocytic leukemia, non-Hodgkins lymphoma, and pancreatic, colon, lung, and prostate cancers [proteasome inhibitor]
Melting Point: 122-124 °C
Index of Refraction: 1.564 
Molar Refractivity: 102.97 cm³ 
Molar Volume: 316.5 cm³ 
Surface Tension: 53.2 dyne/cm 
Density of Bortezomib (CAS NO.179324-69-7): 1.214 g/cm³

In 1995, Bortezomib was first synthesized at a company called Myogenics, which soon changed its name to ProScript.
Bortezomib is the first proteasome inhibitor to be approved b the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cel.It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma.

It is used as a medicine to treat some refractory disease, for example relapsed multiple myeloma and mantle cell lymphoma.

 Bortezomib (CAS NO.179324-69-7), its Synonyms are ((1R)-3-Methyl-1-(((2S)-3-phenyl-2-((pyrazinylcarbonyl)amino)propanoyl)amino)butyl)boronic acid ; Boronic acid, ((1R)-3-methyl-1-(((2S)-1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)- ; N-((1S)-1-Benzyl-2-(((1R)-1-(dihydroxyboranyl)-3-methylbutyl)amino)-2-oxoethyl)pyrazinecarboxamide ; Velcade . It is yellow solid.